Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors...
Gespeichert in:
| Veröffentlicht in: | Microbes and infection 2022-09, Vol.24 (6-7), p.104976-104976, Article 104976 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104976 |
|---|---|
| container_issue | 6-7 |
| container_start_page | 104976 |
| container_title | Microbes and infection |
| container_volume | 24 |
| creator | Anastasi, Emanuela Marziali, Marco Preziosi, Adele Berardelli, Elena Losardo, Anna Annunziata Ribersani, Michela Pugliese, Pellegrina Farina, Antonella Mancini, Patrizia Angeloni, Antonio |
| description | One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean±SD; TM=1917,21±1384,49; HBD=2039,81±1064,44; p=0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p< 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty. |
| doi_str_mv | 10.1016/j.micinf.2022.104976 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8977376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1286457922000466</els_id><sourcerecordid>2647653922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-dbac06a4194592082badfbb9971dc027a9772cb7840280ae4f20ebf42603b4903</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1ERT_gHyDkYzlksR3Hji9IywraSv2Q2kXiZtnOhHoVx4udrNR_j6stBS49jTWeed-ZeRB6T8mCEio-bRbBOz_2C0YYKymupHiFjqgUqpKU_3hd3qwVFW-kOkTHOW8IoY0U_A06rJu6pXWjjlB3PoeYzIAvQphHwAnyNo4Z8BTxKgafRjM94NMv12sqmGUf8d3y9q5axR3D4fZ6iXfGlSEA-xGv781gcobgDb4ym5jw1kwexim_RQe9GTK8e4on6Pu3r-vVeXV5c3axWl5WrqF8qjprHBGGU8UbxUjLrOl6a5WStHOESaOkZM7KlhPWEgO8ZwRsz5kgteWK1Cfo8153O9sAnSveZTW9TT6Y9KCj8fr_n9Hf659xp9uiXEtRBE6fBFL8NUOedPDZwTCYEeKcNRNciqZWjJVSvi91KeacoH-2oUQ_AtIbvQekHwHpPaDS9uHfEZ-b_hD5uwOUQ-08JJ1dOaKDzidwk-6if9nhNxpVoxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2647653922</pqid></control><display><type>article</type><title>Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anastasi, Emanuela ; Marziali, Marco ; Preziosi, Adele ; Berardelli, Elena ; Losardo, Anna Annunziata ; Ribersani, Michela ; Pugliese, Pellegrina ; Farina, Antonella ; Mancini, Patrizia ; Angeloni, Antonio</creator><creatorcontrib>Anastasi, Emanuela ; Marziali, Marco ; Preziosi, Adele ; Berardelli, Elena ; Losardo, Anna Annunziata ; Ribersani, Michela ; Pugliese, Pellegrina ; Farina, Antonella ; Mancini, Patrizia ; Angeloni, Antonio</creatorcontrib><description>One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean±SD; TM=1917,21±1384,49; HBD=2039,81±1064,44; p=0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p< 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.</description><identifier>ISSN: 1286-4579</identifier><identifier>EISSN: 1769-714X</identifier><identifier>DOI: 10.1016/j.micinf.2022.104976</identifier><identifier>PMID: 35381359</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antibodies, Viral ; beta-Thalassemia ; BNT162 Vaccine ; COVID-19 - prevention & control ; Humans ; humoral response ; Immunity, Humoral ; mRNA Vaccines ; RNA, Viral ; Sars-Cov 2 ; SARS-CoV-2 - genetics ; Short Communication ; Spike Glycoprotein, Coronavirus - genetics ; Thalassemia major ; Vaccination ; Vaccines, Synthetic ; Viral Vaccines</subject><ispartof>Microbes and infection, 2022-09, Vol.24 (6-7), p.104976-104976, Article 104976</ispartof><rights>2022 Institut Pasteur</rights><rights>Copyright © 2022 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</rights><rights>2022 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. 2022 Institut Pasteur</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-dbac06a4194592082badfbb9971dc027a9772cb7840280ae4f20ebf42603b4903</citedby><cites>FETCH-LOGICAL-c514t-dbac06a4194592082badfbb9971dc027a9772cb7840280ae4f20ebf42603b4903</cites><orcidid>0000-0002-5124-3219 ; 0000-0002-8629-0971 ; 0000-0003-0556-2056</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1286457922000466$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35381359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anastasi, Emanuela</creatorcontrib><creatorcontrib>Marziali, Marco</creatorcontrib><creatorcontrib>Preziosi, Adele</creatorcontrib><creatorcontrib>Berardelli, Elena</creatorcontrib><creatorcontrib>Losardo, Anna Annunziata</creatorcontrib><creatorcontrib>Ribersani, Michela</creatorcontrib><creatorcontrib>Pugliese, Pellegrina</creatorcontrib><creatorcontrib>Farina, Antonella</creatorcontrib><creatorcontrib>Mancini, Patrizia</creatorcontrib><creatorcontrib>Angeloni, Antonio</creatorcontrib><title>Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients</title><title>Microbes and infection</title><addtitle>Microbes Infect</addtitle><description>One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean±SD; TM=1917,21±1384,49; HBD=2039,81±1064,44; p=0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p< 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.</description><subject>Antibodies, Viral</subject><subject>beta-Thalassemia</subject><subject>BNT162 Vaccine</subject><subject>COVID-19 - prevention & control</subject><subject>Humans</subject><subject>humoral response</subject><subject>Immunity, Humoral</subject><subject>mRNA Vaccines</subject><subject>RNA, Viral</subject><subject>Sars-Cov 2</subject><subject>SARS-CoV-2 - genetics</subject><subject>Short Communication</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Thalassemia major</subject><subject>Vaccination</subject><subject>Vaccines, Synthetic</subject><subject>Viral Vaccines</subject><issn>1286-4579</issn><issn>1769-714X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi1ERT_gHyDkYzlksR3Hji9IywraSv2Q2kXiZtnOhHoVx4udrNR_j6stBS49jTWeed-ZeRB6T8mCEio-bRbBOz_2C0YYKymupHiFjqgUqpKU_3hd3qwVFW-kOkTHOW8IoY0U_A06rJu6pXWjjlB3PoeYzIAvQphHwAnyNo4Z8BTxKgafRjM94NMv12sqmGUf8d3y9q5axR3D4fZ6iXfGlSEA-xGv781gcobgDb4ym5jw1kwexim_RQe9GTK8e4on6Pu3r-vVeXV5c3axWl5WrqF8qjprHBGGU8UbxUjLrOl6a5WStHOESaOkZM7KlhPWEgO8ZwRsz5kgteWK1Cfo8153O9sAnSveZTW9TT6Y9KCj8fr_n9Hf659xp9uiXEtRBE6fBFL8NUOedPDZwTCYEeKcNRNciqZWjJVSvi91KeacoH-2oUQ_AtIbvQekHwHpPaDS9uHfEZ-b_hD5uwOUQ-08JJ1dOaKDzidwk-6if9nhNxpVoxQ</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Anastasi, Emanuela</creator><creator>Marziali, Marco</creator><creator>Preziosi, Adele</creator><creator>Berardelli, Elena</creator><creator>Losardo, Anna Annunziata</creator><creator>Ribersani, Michela</creator><creator>Pugliese, Pellegrina</creator><creator>Farina, Antonella</creator><creator>Mancini, Patrizia</creator><creator>Angeloni, Antonio</creator><general>Elsevier Masson SAS</general><general>Institut Pasteur. Published by Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5124-3219</orcidid><orcidid>https://orcid.org/0000-0002-8629-0971</orcidid><orcidid>https://orcid.org/0000-0003-0556-2056</orcidid></search><sort><creationdate>20220901</creationdate><title>Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients</title><author>Anastasi, Emanuela ; Marziali, Marco ; Preziosi, Adele ; Berardelli, Elena ; Losardo, Anna Annunziata ; Ribersani, Michela ; Pugliese, Pellegrina ; Farina, Antonella ; Mancini, Patrizia ; Angeloni, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-dbac06a4194592082badfbb9971dc027a9772cb7840280ae4f20ebf42603b4903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Viral</topic><topic>beta-Thalassemia</topic><topic>BNT162 Vaccine</topic><topic>COVID-19 - prevention & control</topic><topic>Humans</topic><topic>humoral response</topic><topic>Immunity, Humoral</topic><topic>mRNA Vaccines</topic><topic>RNA, Viral</topic><topic>Sars-Cov 2</topic><topic>SARS-CoV-2 - genetics</topic><topic>Short Communication</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Thalassemia major</topic><topic>Vaccination</topic><topic>Vaccines, Synthetic</topic><topic>Viral Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anastasi, Emanuela</creatorcontrib><creatorcontrib>Marziali, Marco</creatorcontrib><creatorcontrib>Preziosi, Adele</creatorcontrib><creatorcontrib>Berardelli, Elena</creatorcontrib><creatorcontrib>Losardo, Anna Annunziata</creatorcontrib><creatorcontrib>Ribersani, Michela</creatorcontrib><creatorcontrib>Pugliese, Pellegrina</creatorcontrib><creatorcontrib>Farina, Antonella</creatorcontrib><creatorcontrib>Mancini, Patrizia</creatorcontrib><creatorcontrib>Angeloni, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Microbes and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anastasi, Emanuela</au><au>Marziali, Marco</au><au>Preziosi, Adele</au><au>Berardelli, Elena</au><au>Losardo, Anna Annunziata</au><au>Ribersani, Michela</au><au>Pugliese, Pellegrina</au><au>Farina, Antonella</au><au>Mancini, Patrizia</au><au>Angeloni, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients</atitle><jtitle>Microbes and infection</jtitle><addtitle>Microbes Infect</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>24</volume><issue>6-7</issue><spage>104976</spage><epage>104976</epage><pages>104976-104976</pages><artnum>104976</artnum><issn>1286-4579</issn><eissn>1769-714X</eissn><abstract>One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean±SD; TM=1917,21±1384,49; HBD=2039,81±1064,44; p=0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p< 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>35381359</pmid><doi>10.1016/j.micinf.2022.104976</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5124-3219</orcidid><orcidid>https://orcid.org/0000-0002-8629-0971</orcidid><orcidid>https://orcid.org/0000-0003-0556-2056</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1286-4579 |
| ispartof | Microbes and infection, 2022-09, Vol.24 (6-7), p.104976-104976, Article 104976 |
| issn | 1286-4579 1769-714X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8977376 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Viral beta-Thalassemia BNT162 Vaccine COVID-19 - prevention & control Humans humoral response Immunity, Humoral mRNA Vaccines RNA, Viral Sars-Cov 2 SARS-CoV-2 - genetics Short Communication Spike Glycoprotein, Coronavirus - genetics Thalassemia major Vaccination Vaccines, Synthetic Viral Vaccines |
| title | Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A57%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Humoral%20Immune%20response%20to%20Comirnaty%20(BNT162b2)%20SARS-Cov2%20mRNA%20vaccine%20in%20Thalassemia%20Major%20patients&rft.jtitle=Microbes%20and%20infection&rft.au=Anastasi,%20Emanuela&rft.date=2022-09-01&rft.volume=24&rft.issue=6-7&rft.spage=104976&rft.epage=104976&rft.pages=104976-104976&rft.artnum=104976&rft.issn=1286-4579&rft.eissn=1769-714X&rft_id=info:doi/10.1016/j.micinf.2022.104976&rft_dat=%3Cproquest_pubme%3E2647653922%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2647653922&rft_id=info:pmid/35381359&rft_els_id=S1286457922000466&rfr_iscdi=true |